Lung

Explore a Clinical Trial for Lung Cancer

Merck is passionate about improving health. We are committed to accelerating every step in the journey in our quest to bring treatment options to people with cancer. 

Clinical trials for lung cancer are underway and currently enrolling patients. If you have patients with lung cancer, you may want to consider a Merck Oncology Clinical Trial. 

Keynote clinical trials are currently enrolling patients with non-small cell and small cell lung cancer. To see if your patients qualify for one of these trials, contact our clinical trial information center at 1-888-577-8839. If you are interested in partnering with us as an investigator, call 1-800-290-4339.

17

Active Trials

8

Trials Recruiting

131

US Trial Locations

Explore Active Clinical Trials

Trial Description Trial Number Condition Phase Status
Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab With or Without Lenvatinib as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer
7902-006 Nonsquamous Non-small Cell Lung Cancer Phase 3 Recruiting
Efficacy and Safety Study of Pembrolizumab With or Without Lenvatinib in Adults With Programmed Cell Death-Ligand 1 -Positive Treatment-naïve Non-small Cell Lung Cancer
7902-007 Non-small Cell Lung Cancer Phase 3 Recruiting
Study of Pembrolizumab vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy
091 Non-small Cell Lung Cancer Phase 3 Recruiting
Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-small Cell Lung Cancer
598 Carcinoma, Non-Small-Cell Lung Phase 3 Recruiting
Efficacy and Safety of Pembrolizumab With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer
671 Early-stage Non-small Cell Lung Cancer Phase 3 Recruiting
Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI) -Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
789 Non-small Cell Lung Cancer Phase 3 Recruiting
A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC.
799 Non-small Cell Lung Cancer Phase 2 Recruiting
Efficacy and Safety Study of Stereotactic Body Radiotherapy With or Without Pembrolizumab in Adults With Medically Inoperable Stage I or IIA Non-Small Cell Lung Cancer
867 Non-Small Cell Lung Cancer Phase 3 Recruiting
Study of Two Doses of Pembrolizumab Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer
010 Non Small Cell Lung Cancer (NSCLC) Phase 2/Phase 3 Active, not recruiting
Study of Pembrolizumab Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer
011
  • Solid Tumor
  • Non-small Cell Lung Cancer
  • Small Cell Lung Cancer
Phase 1 Active, not recruiting
A Study of Pembrolizumab in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer
021 Non-small Cell Lung Carcinoma Phase 1/Phase 2 Active, not recruiting
Study of Pembrolizumab Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer
024 Non-Small Cell Lung Carcinoma Phase 3 Active, not recruiting
Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Pembrolizumab in Chinese Participants With Non-Small-Cell Lung Cancer
032 Non-Small-Cell Lung Cancer Phase 1 Active, not recruiting
Study of Pembrolizumab Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 -Positive Advanced or Metastatic Non-Small Cell Lung Cancer
042 Non-small Cell Lung Cancer Phase 3 Active, not recruiting
Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab in Participants With First Line Metastatic Non-squamous Non-small Cell Lung Cancer
189 Non-Small-Cell Lung Carcinoma Phase 3 Active, not recruiting
A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer
407 Non-small Cell Lung Cancer Phase 3 Active, not recruiting
A Study of Pembrolizumab in Combination With Etoposide/Platinum for Participants With Extensive Stage Small Cell Lung Cancer
604
  • Small Cell Lung Cancer
  • SCLC
Phase 3 Active, not recruiting